Erratum: The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association (Circulation (2015) 132 (2167-2192) DOI: 10.1161/CIR.0000000000000297);The Agenda for Familial Hypercholesterolemia: A Scientific Statement from the American Heart Association

Circulation

Volumn 132, Issue 22, 2015, Pages 2167-2192

  Gidding, Samuel S ^a   Champagne, Mary Ann ^b   De Ferranti, Sarah D ^c   Defesche, Joep ^d   Ito, Matthew K ^e   Knowles, Joshua W ^f   McCrindle, Brian ^g   Raal, Frederick ^h   Rader, Daniel ⁱ   Santos, Raul D ^j   Lopes Virella, Maria ^k   Watts, Gerald F ^l   Wierzbicki, Anthony S ^m  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f STANFORD UNIVERSITY   (United States)

^g Hospital for Sick Kids   (United States)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j UNIVERSITY OF SÃO PAULO   (Brazil)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^m ST THOMAS HOSPITAL   (United Kingdom)

more..

Author keywords

AHA Scientific Statements; atherosclerosis; coronary disease; genetic testing; hydroxymethylglutaryl CoA reductase inhibitors; hyperlipoproteinemia type II; receptors, LDL

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULTHOOD; ARTICLE; ATHEROSCLEROSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; EVIDENCE BASED PRACTICE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC SCREENING; HEALTH ECONOMICS; HEART MUSCLE ISCHEMIA; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIPOPROTEIN APHERESIS SYSTEM; LIVER TRANSPLANTATION; MEDICAL SOCIETY; MINORITY GROUP; MOLECULAR PATHOLOGY; PATIENT CARE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SUBCLINICAL ATHEROSCLEROSIS; EPIDEMIOLOGY; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; UNITED STATES;

AMERICAN HEART ASSOCIATION; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; RECEPTORS, LDL; UNITED STATES;

EID: 84949321606     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000349     Document Type: Erratum

References (206)

1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjarg-Hansen A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478-390a. doi: 10.1093/eurheartj/eht273.
2. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:133-140. doi: 10.1016/j.jacl.2011.03.001.
3. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol. 2014;8:148-172. doi: 10.1016/j. jacl.2014.01.002.
4. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29:431-438. doi: 10.1161/ATVBAHA.108.179564.
5. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, Harrison SC, Li K, Drenos F, Karpe F, Neil HA, Descamps OS, Langenberg C, Lench N, Kivimaki M, Whittaker J, Hingorani AD, Kumari M, Humphries SE. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013;381:1293-1301. doi: 10.1016/S0140-6736(12)62127-8.
6. Taylor A, Wang D, Patel K, Whittall R, Wood G, Farrer M, Neely RD, Fairgrieve S, Nair D, Barbir M, Jones JL, Egan S, Everdale R, Lolin Y, Hughes E, Cooper JA, Hadfield SG, Norbury G, Humphries SE. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet. 2010;77:572-580. doi: 10.1111/j.1399-0004.2009.01356.x.
7. Hovingh GK, Davidson MH, Kastelein JJ, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013;34:962-971. doi: 10.1093/eurheartj/eht015.
8. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA Sr, Flack JM. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631-2639. doi: 10.1016/j.jacc.2012.09.017.
9. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, Marais AD. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipidlowering therapy. Circulation. 2011;124:2202-2207. doi: 10.1161/CIRCULATIONAHA.111.042523.
10. Neil HA, Hammond T, Mant D, Humphries SE. Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002. BMJ. 2004;328:500-501. doi: 10.1136/bmj.328.7438.500.
11. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.
12. Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012;19:1043-1060.
13. Rynkiewicz A, Cybulska B, Banach M, Filipiak K, Guzik T, Idzior-Walu? B, Imiela J, Jankowski P, K?osiewicz-Latoszek L, Limon J, My?liwiec M, Opolski G, Steciwko A, St?pi?ska J, Zdrojewski T. Management of familial heterozygous hypercholesterolemia: position paper of the Polish Lipid Expert Forum. J Clin Lipidol. 2013;7:217-221. doi: 10.1016/j. jacl.2013.01.005.
14. Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, Roeters van Lennep JE, Stalenhoef AF, Wiegman A, de Graaf J, Fouchier SW, Kastelein JJ, Hovingh GK. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2015;36:560-565. doi: 10.1093/eurheartj/ehu058.
15. Leren TP. Cascade genetic screening for familial hypercholesterolemia. Clin Genet. 2004;66:483-487. doi: 10.1111/j.1399-0004.2004.00320.x.
16. Homsma SJ, Huijgen R, Middeldorp S, Sijbrands EJ, Kastelein JJ. Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance [published correction appears in Eur J Hum Genet. 2008;16:275]. Eur J Hum Genet. 2008;16:14-17. doi: 10.1038/sj.ejhg.5201940.
17. Huijgen R, Homsma SJ, Hutten BA, Kindt I, Vissers MN, Kastelein JJ, van Rijckevorsel JL. Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study. Eur J Hum Genet. 2012;20:722-728. doi: 10.1038/ejhg.2012.5.
18. Frich JC, Malterud K, Fugelli P. How do patients at risk portray candidates for coronary heart disease? A qualitative interview study. Scand J Prim Health Care. 2007;25:112-116. doi: 10.1080/02813430601183215.
19. Frich JC, Ose L, Malterud K, Fugelli P. Perceived vulnerability to heart disease in patients with familial hypercholesterolemia: a qualitative interview study. Ann Fam Med. 2006;4:198-204. doi: 10.1370/afm.529.
20. Claassen L, Henneman L, Kindt I, Marteau TM, Timmermans DR. Perceived risk and representations of cardiovascular disease and preventive behaviour in people diagnosed with familial hypercholesterolemia: a cross-sectional questionnaire study. J Health Psychol. 2010;15:33-43. doi: 10.1177/1359105309345170.
21. Claassen L, Henneman L, van der Weijden T, Marteau TM, Timmermans DR. Being at risk for cardiovascular disease: perceptions and preventive behavior in people with and without a known genetic predisposition. Psychol Health Med. 2012;17:511-521. doi: 10.1080/13548506.2011.644246.
22. de Jongh S, Kerckhoffs MC, Grootenhuis MA, Bakker HD, Heymans HS, Last BF. Quality of life, anxiety and concerns among statin-treated children with familial hypercholesterolaemia and their parents. Acta Paediatr. 2003;92:1096-1101.
23. Agard A, Bolmsjo IA, Hermeren G, Wahlstom J. Familial hypercholesterolemia: ethical, practical and psychological problems from the perspective of patients. Patient Educ Couns. 2005;57:162-167. doi: 10.1016/j. pec.2004.05.010.
24. Retterstol K, Stugaard M, Gorbitz C, Ose L. Results of intensive long-term treatment of familial hypercholesterolemia. Am J Cardiol. 1996;78:1369-1374.
25. Grasdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, Brekke M, Retterstol K, Arnesen KE, Ose L. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2012;6:331-339. doi: 10.1016/j.jacl.2012.03.004.
26. Schiel R, Bambauer R, Muller UA. Four years' treatment efficacy of patients with severe hyperlipidemia: lipid lowering drugs versus LDLapheresis. Int J Artif Organs. 1995;18:786-793.
27. Hardcastle SJ, Legge E, Laundy CS, Egan SJ, French R, Watts GF, Hagger MS. Patients' perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment. Int J Behav Med. 2015;22:92-100. doi: 10.1007/s12529-014-9402-x.
28. Fagge CH. Xanthomatous diseases of the skin. Trans Pathol Soc London. 1873;24:242-250.
29. Muller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand. 1938;89:75-84.
30. Wilkinson CF Jr, Hand EA, Fliegelman MT. Essential familial hypercholesterolemia. Ann Intern Med. 1948;29:671-686.
31. Khachadurian AK. The inheritance of essential familial hypercholesterolemia. Am J Med. 1964;37:402-407.
32. Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973;70:2804-2808.
33. Brown MS, Goldstein JL. Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science. 1974;185:61-63.
34. Anderson RG, Goldstein JL, Brown MS. Localization of low density lipoprotein receptors on plasma membrane of normal human fibroblasts and their absence in cells from a familial hypercholesterolemia homozygote. Proc Natl Acad Sci U S A. 1976;73:2434-2438.
35. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
36. Lindgren V, Luskey KL, Russell DW, Francke U. Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes. Proc Natl Acad Sci U S A. 1985;82:8567-8571.
37. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992;1:445-466. doi: 10.1002/humu.1380010602.
38. Koivisto UM, Hubbard AL, Mellman I. A novel cellular phenotype for familial hypercholesterolemia due to a defect in polarized targeting of LDL receptor. Cell. 2001;105:575-585.
39. Schneider WJ, Beisiegel U, Goldstein JL, Brown MS. Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164,000 molecular weight. J Biol Chem. 1982;257:2664-2673.
40. Koivisto PV, Koivisto UM, Kovanen PT, Gylling H, Miettinen TA, Kontula K. Deletion of exon 15 of the LDL receptor gene is associated with a mild form of familial hypercholesterolemia. FH-Espoo. Arterioscler Thromb. 1993;13:1680-1688.
41. Usifo E, Leigh SE, Whittall RA, Lench N, Taylor A, Yeats C, Orengo CA, Martin AC, Celli J, Humphries SE. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet. 2012;76:387-401. doi: 10.1111/j.1469-1809.2012.00724.x.
42. British Heart Foundation. LOVD database. http://www.ucl.ac.uk/fh. Accessed September 3, 2015.
43. Defesche JC, Pricker KL, Hayden MR, van der Ende BE, Kastelein JJ. Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. Arch Intern Med. 1993;153:2349-2356.
44. Lange LA, Hu Y, Zhang H, Xue C, Schmidt EM, Tang ZZ, Bizon C, Lange EM, Smith JD, Turner EH, Jun G, Kang HM, Peloso G, Auer P, Li KP, Flannick J, Zhang J, Fuchsberger C, Gaulton K, Lindgren C, Locke A, Manning A, Sim X, Rivas MA, Holmen OL, Gottesman O, Lu Y, Ruderfer D, Stahl EA, Duan Q, Li Y, Durda P, Jiao S, Isaacs A, Hofman A, Bis JC, Correa A, Griswold ME, Jakobsdottir J, Smith AV, Schreiner PJ, Feitosa MF, Zhang Q, Huffman JE, Crosby J, Wassel CL, Do R, Franceschini N, Martin LW, Robinson JG, Assimes TL, Crosslin DR, Rosenthal EA, Tsai M, Rieder MJ, Farlow DN, Folsom AR, Lumley T, Fox ER, Carlson CS, Peters U, Jackson RD, van Duijn CM, Uitterlinden AG, Levy D, Rotter JI, Taylor HA, Gudnason V Jr, Siscovick DS, Fornage M, Borecki IB, Hayward C, Rudan I, Chen YE, Bottinger EP, Loos RJ, Satrom P, Hveem K, Boehnke M, Groop L, McCarthy M, Meitinger T, Ballantyne CM, Gabriel SB, O'Donnell CJ, Post WS, North KE, Reiner AP, Boerwinkle E, Psaty BM, Altshuler D, Kathiresan S, Lin DY, Jarvik GP, Cupples LA, Kooperberg C, Wilson JG, Nickerson DA, Abecasis GR, Rich SS, Tracy RP, Willer CJ; NHLBI Grand Opportunity Exome Sequencing Project. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014;94:233-245. doi: 10.1016/j.ajhg.2014.01.010.
45. Boren J, Ekstrom U, Agren B, Nilsson-Ehle P, Innerarity TL. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem. 2001;276:9214-9218. doi: 10.1074/jbc.M008890200.
46. Thomas ER, Atanur SS, Norsworthy PJ, Encheva V, Snijders AP, Game L, Vandrovcova J, Siddiq A, Seed M, Soutar AK, Aitman TJ. Identification and biochemical analysis of a novel APOB mutation that causes autosomal dominant hypercholesterolemia. Mol Genet Genomic Med. 2013;1:155-161. doi: 10.1002/mgg3.17.
47. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156. doi: 10.1038/ng1161.
48. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53:2515-2524. doi: 10.1194/jlr.R026658.
49. Awan Z, Choi HY, Stitziel N, Ruel I, Bamimore MA, Husa R, Gagnon MH, Wang RH, Peloso GM, Hegele RA, Seidah NG, Kathiresan S, Genest J. APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis. 2013;231:218-222. doi: 10.1016/j. atherosclerosis.2013.09.007.
50. Marduel M, Ouguerram K, Serre V, Bonnefont-Rousselot D, Marques-Pinheiro A, Erik Berge K, Devillers M, Luc G, Lecerf JM, Tosolini L, Erlich D, Peloso GM, Stitziel N, Nitchke P, Jais JP; French Research Network on ADH, Abifadel M, Kathiresan S, Leren TP, Rabes JP, Boileau C, Varret M. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum Mutat. 2013;34:83-87. doi: 10.1002/humu.22215.
51. Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2003;23:1963-1970. doi: 10.1161/01. ATV.0000094410.66558.9A.
52. Stitziel NO, Fouchier SW, Sjouke B, Peloso GM, Moscoso AM, Auer PL, Goel A, Gigante B, Barnes TA, Melander O, Orho-Melander M, Duga S, Sivapalaratnam S, Nikpay M, Martinelli N, Girelli D, Jackson RD, Kooperberg C, Lange LA, Ardissino D, McPherson R, Farrall M, Watkins H, Reilly MP, Rader DJ, de Faire U, Schunkert H, Erdmann J, Samani NJ, Charnas L, Altshuler D, Gabriel S, Kastelein JJ, Defesche JC, Nederveen AJ, Kathiresan S, Hovingh GK; National Heart, Lung, and Blood Institute GO Exome Sequencing Project. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2013;33:2909-2914. doi: 10.1161/ATVBAHA.113.302426.
53. Jeenah M, September W, Graadt van Roggen F, de Villiers W, Seftel H, Marais D. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Atherosclerosis. 1993;98:51-58.
54. Gudnason V, Day IN, Humphries SE. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia. Arterioscler Thromb. 1994;14:1717-1722.
55. Sun XM, Patel DD, Bhatnagar D, Knight BL, Soutar AK. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. Arterioscler Thromb Vasc Biol. 1995;15:219-227.
56. Vohl MC, Gaudet D, Moorjani S, Tremblay G, Perron P, Gagne C, Lesiege D, Bergeron J, Lupien PJ, Despres JP. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia. Eur J Clin Invest. 1997;27:366-373.
57. Sijbrands EJ, Lombardi MP, Westendorp RG, Leuven JA, Meinders AE, Van der Laarse A, Frants RR, Havekes LM, Smelt AH. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis. 1998;136:247-254.
58. Graham CA, McClean E, Ward AJ, Beattie ED, Martin S, O'Kane M, Young IS, Nicholls DP. Mutation screening and genotype:phenotype correlation in familial hypercholesterolaemia. Atherosclerosis. 1999;147:309-316.
59. Gaudet D, Vohl MC, Couture P, Moorjani S, Tremblay G, Perron P, Gagne C, Despres JP. Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25-49 years) versus middle-aged (50-64 years) men. Atherosclerosis. 1999;143:153-161.
60. Versmissen J, Oosterveer DM, Yazdanpanah M, Dehghan A, Holm H, Erdman J, Aulchenko YS, Thorleifsson G, Schunkert H, Huijgen R, Vongpromek R, Uitterlinden AG, Defesche JC, van Duijn CM, Mulder M, Dadd T, Karlsson HD, Ordovas J, Kindt I, Jarman A, Hofman A, van Vark-van der Zee L, Blommesteijn-Touw AC, Kwekkeboom J, Liem AH, van der Ouderaa FJ, Calandra S, Bertolini S, Averna M, Langslet G, Ose L, Ros E, Almagro F, de Leeuw PW, Civeira F, Masana L, Pinto X, Simoons ML, Schinkel AF, Green MR, Zwinderman AH, Johnson KJ, Schaefer A, Neil A, Witteman JC, Humphries SE, Kastelein JJ, Sijbrands EJ. Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. Eur J Hum Genet. 2015;23:381-387. doi: 10.1038/ejhg.2014.101.
61. de Sauvage Nolting PR, Defesche JC, Buirma RJ, Hutten BA, Lansberg PJ, Kastelein JJ. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med. 2003;253:161-168.
62. McMahan CA, Gidding SS, Fayad ZA, Zieske AW, Malcom GT, Tracy RE, Strong JP, McGill HC Jr. Risk scores predict atherosclerotic lesions in young people. Arch Intern Med. 2005;165:883-890. doi: 10.1001/archinte.165.8.883.
63. McMahan CA, Gidding SS, Viikari JS, Juonala M, Kahonen M, Hutri-Kahonen N, Jokinen E, Taittonen L, Pietikainen M, McGill HC Jr, Raitakari OT. Association of Pathobiologic Determinants of Atherosclerosis in Youth risk score and 15-year change in risk score with carotid artery intima-media thickness in young adults (from the Cardiovascular Risk in Young Finns Study). Am J Cardiol. 2007;100:1124-1129. doi: 10.1016/j.amjcard.2007.05.035.
64. Das S, Zhang S, Mitchell D, Gidding SS. Metabolic syndrome with early aortic atherosclerosis in a child. J Cardiometab Syndr. 2006;1:286-287.
65. Kusters DM, Hutten BA, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Langslet G, Kastelein JJ, Wiegman A. Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia. J Clin Lipidol. 2013;7:408-413. doi: 10.1016/j.jacl.2013.06.010.
66. Gidding SS, Bookstein LC, Chomka EV. Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. Circulation. 1998;98:2580-2583.
67. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49:476-488.
68. Risk of fatal coronary heart disease in familial hypercholesterolaemia: Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ. 1991;303:893-896.
69. Oosterveer DM, Versmissen J, Yazdanpanah M, Hamza TH, Sijbrands EJ. Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis. Atherosclerosis. 2009;207:311-317. doi: 10.1016/j.atherosclerosis.2009.04.009.
70. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Lowdensity lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation. 2002;106:3031-3036.
71. Jansen AC, van Wissen S, Defesche JC, Kastelein JJ. Phenotypic variability in familial hypercholesterolaemia: an update. Curr Opin Lipidol. 2002;13:165-171.
72. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ. 2001;322:1019-1023.
73. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322:1494-1499. doi: 10.1056/NEJM199005243222104.
74. Alonso R, Andres E, Mata N, Fuentes-Jimenez F, Badimon L, Lopez-Miranda J, Padro T, Muniz O, Diaz-Diaz JL, Mauri M, Ordovas JM, Mata P; SAFEHEART Investigators. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014;63:1982-1989. doi: 10.1016/j.jacc.2014.01.063.
75. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjarg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853. doi: 10.1093/eurheartj/ehq386.
76. Descamps OS, de Meester A, Cheron P, Kastelein JJ, Heller FR. Silent ischaemia in familial hypercholesterolemia. Atheroscler Suppl. 2003;4:7-8.
77. Mouratidis B, Vaughan-Neil EF, Gilday DL, Ash JM, Cullen-Dean G, McIntyre S, MacMillan JH, Rose V. Detection of silent coronary artery disease in adolescents and young adults with familial hypercholesterolemia by single-photon emission computed tomography thallium-201 scanning. Am J Cardiol. 1992;70:1109-1112.
78. Michaelides AP, Fourlas CA, Pitsavos C, Andrikopoulos GK, Skoumas I, Kartalis A, Katsaros A, Stougiannos P, Stefanadis CI. Exercise testing in asymptomatic patients with heterozygous familial hypercholesterolaemia. Coron Artery Dis. 2004;15:461-465.
79. Pitsavos CH, Chrysohoou C, Panagiotakos DB, Kokkinos P, Skoumas J, Papaioannou I, Michaelides AP, Singh S, Stefanadis CI. Exercise capacity and heart rate recovery as predictors of coronary heart disease events, in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173:347-352. doi: 10.1016/j.atherosclerosis.2003.12.027.
80. Neefjes LA, Ten Kate GJ, Rossi A, Galema-Boers AJ, Langendonk JG, Weustink AC, Moelker A, Nieman K, Mollet NR, Krestin GP, Sijbrands EJ, de Feyter PJ. CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia. Heart. 2011;97:1151-1157. doi: 10.1136/hrt.2010.220699.
81. Wendelhag I, Wiklund O, Wikstrand J. Arterial wall thickness in familial hypercholesterolemia: ultrasound measurement of intima-media thickness in the common carotid artery. Arterioscler Thromb. 1992;12:70-77.
82. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJ, Kastelein JJ. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004;363:369-370. doi: 10.1016/S0140-6736(04)15467-6.
83. Martinez LR, Miname MH, Bortolotto LA, Chacra AP, Rochitte CE, Sposito AC, Santos RD. No correlation and low agreement of imaging and inflammatory atherosclerosis' markers in familial hypercholesterolemia. Atherosclerosis. 2008;200:83-88. doi: 10.1016/j.atherosclerosis. 2007.12.014.
84. Miname MH, Ribeiro MS 2nd, Parga Filho J, Avila LF, Bortolotto LA, Martinez LR, Rochitte CE, Santos RD. Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. Atherosclerosis. 2010;213:486-491. doi: 10.1016/j.atherosclerosis.2010.10.001.
85. van Wijk DF, Sjouke B, Figueroa A, Emami H, van der Valk FM, MacNabb MH, Hemphill LC, Schulte DM, Koopman MG, Lobatto ME, Verberne HJ, Fayad ZA, Kastelein JJ, Mulder WJ, Hovingh GK, Tawakol A, Stroes ES. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. J Am Coll Cardiol. 2014;64:1418-1426. doi: 10.1016/j.jacc.2014.01.088.
86. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753. doi: 10.1161/CIRCULATIONAHA.107.699579.
87. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788-795. doi: 10.1001/jama.2012.9624.
88. Kramer CK, Zinman B, Gross JL, Canani LH, Rodrigues TC, Azevedo MJ, Retnakaran R. Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis. BMJ. 2013;346:f1654.
89. Clarke RE, Padayachee ST, Preston R, McMahon Z, Gordon M, Graham C, Crook MA, Wierzbicki AS. Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. Heart. 2013;99:175-180. doi: 10.1136/heartjnl-2012-302917.
90. Cho I, Chang HJ, Sung JM, Pencina MJ, Lin FY, Dunning AM, Achenbach S, Al-Mallah M, Berman DS, Budoff MJ, Callister TQ, Chow BJ, Delago A, Hadamitzky M, Hausleiter J, Maffei E, Cademartiri F, Kaufmann P, Shaw LJ, Raff GL, Chinnaiyan KM, Villines TC, Cheng V, Nasir K, Gomez M, Min JK; CONFIRM Investigators. Coronary computed tomographic angiography and risk of all-cause mortality and nonfatal myocardial infarction in subjects without chest pain syndrome from the CONFIRM Registry (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry). Circulation. 2012;126:304-313. doi: 10.1161/CIRCULATIONAHA.111.081380.
91. Vilades Medel D, Leta Petracca R, Carreras Costa F, Cardona Olle M, Barros Membrilla A, Hidalgo Perez JA, Pujadas Olano S, Alomar Serrallach X, Franco Peral M, Pons-Llado G. Coronary computed tomographic angiographic findings in asymptomatic patients with heterozygous familial hypercholesterolemia and null allele low-density lipoprotein receptor mutations. Am J Cardiol. 2013;111:955-961. doi: 10.1016/j. amjcard.2012.12.012.
92. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjarg-Hansen A, Watts GF, Averna M, Boileau C, Boren J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management: a position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146-2157. doi: 10.1093/eurheartj/ehu274.
93. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111:1795-1803. doi: 10.1172/JCI18925.
94. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262-268. doi: 10.1016/j.atherosclerosis.2012.02.019.
95. Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol. 2004;15:413-422.
96. Goldstein JL HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. Berlin, Germany: Springer; 2001:2863-2913.
97. Alonso R, Mata P, Zambon D, Mata N, Fuentes-Jimenez F. Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes. Expert Rev Cardiovasc Ther. 2013;11:327-342. doi: 10.1586/erc.13.7.
98. Schmidt HH, Hill S, Makariou EV, Feuerstein IM, Dugi KA, Hoeg JM. Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia. Am J Cardiol. 1996;77:575-580.
99. Nemati MH, Astaneh B, Joubeh A. Triple coronary artery bypass graft in a 10-year-old child with familial hypercholesterolemia. Gen Thorac Cardiovasc Surg. 2009;57:94-97. doi: 10.1007/s11748-008-0335-7.
100. Widhalm K, Binder CB, Kreissl A, Aldover-Macasaet E, Fritsch M, Kroisboeck S, Geiger H. Sudden death in a 4-year-old boy: a near-complete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. J Pediatr. 2011;158:167. doi: 10.1016/j.jpeds.2010.06.027.
101. Haitas B, Baker SG, Meyer TE, Joffe BI, Seftel HC. Natural history and cardiac manifestations of homozygous familial hypercholesterolaemia. Q J Med. 1990;76:731-740.
102. Kawaguchi A, Yutani C, Yamamoto A. Hypercholesterolemic valvulopathy: an aspect of malignant atherosclerosis. Ther Apher Dial. 2003;7:439-443.
103. Santos RD, Miname MH, Martinez LR, Rochitte CE, Chacra AP, Nakandakare ER, Chen D, Schaefer EJ. Non-invasive detection of aortic and coronary atherosclerosis in homozygous familial hypercholesterolemia by 64 slice multi-detector row computed tomography angiography. Atherosclerosis. 2008;197:910-915. doi: 10.1016/j. atherosclerosis.2007.08.017.
104. Rocha VZ, Chacra AP, Salgado W, Miname M, Turolla L, Gagliardi AC, Ribeiro EE, Rocha RP, Avila LF, Pereira A, Nakandakare ER, Santos RD. Extensive xanthomas and severe subclinical atherosclerosis in homozygous familial hypercholesterolemia. J Am Coll Cardiol. 2013;61:2193. doi: 10.1016/j.jacc.2012.11.079.
105. Westwood ME, Raatz HD, Misso K, Burgers L, Redekop K, Lhachimi SK, Armstrong N, Kleijnen J. Systematic review of the accuracy of dual-source cardiac CT for detection of arterial stenosis in difficult to image patient groups. Radiology. 2013;267:387-395. doi: 10.1148/radiol.13121136.
106. Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart. 1998;80:583-590.
107. Tomochika Y, Tanaka N, Ono S, Murata K, Muro A, Yamamura T, Tone T, Iwatate M, Ueda K, Morikuni K, Matsuzaki M. Assessment by transesophageal echography of atherosclerosis of the descending thoracic aorta in patients with hypercholesterolemia. Am J Cardiol. 1999;83:703-709.
108. Summers RM, Andrasko-Bourgeois J, Feuerstein IM, Hill SC, Jones EC, Busse MK, Wise B, Bove KE, Rishforth BA, Tucker E, Spray TL, Hoeg JM. Evaluation of the aortic root by MRI: insights from patients with homozygous familial hypercholesterolemia. Circulation. 1998;98:509-518.
109. Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE, Araujo L, Vohra Y, Defesche JC, Wilson JM, Rader DJ. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102:1438-1443. doi: 10.1016/j.amjcard.2008.07.035.
110. Umans-Eckenhausen MA, Defesche JC, Scheerder RL, Cline F, Kastelein JJ. Tracing of patients with familial hypercholesterolemia in the Netherlands [in Dutch]. Ned Tijdschr Geneeskd. 1999;143:1157-1161.
111. Starr B, Hadfield SG, Hutten BA, Lansberg PJ, Leren TP, Damgaard D, Neil HA, Humphries SE. Development of sensitive and specific age-and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med. 2008;46:791-803. doi: 10.1515/CCLM.2008.135.
112. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72:171-176.
113. Shi Z, Yuan B, Zhao D, Taylor AW, Lin J, Watts GF. Int J Cardiol. 2014;14:845-846.
114. NICE Clinical Guideline 71: Identification and Management of Familial Hypercholesterolaemia. London, UK: National Institute for Health and Clinical Excellence, National Collaborating Centre for Primary Care; 2008.
115. Ademi Z, Watts GF, Pang J, Sijbrands EJ, van Bockxmeer FM, O'Leary P, Geelhoed E, Liew D. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol. 2014;8:390-400. doi: 10.1016/j.jacl.2014.05.008.
116. Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63:1935-1947. doi: 10.1016/j.jacc.2014.01.060.
117. Wald DS, Kasturiratne A, Godoy A, Ma L, Bestwick JP, Brewer N, Wald NJ. Child-parent screening for familial hypercholesterolemia. J Pediatr. 2011;159:865-867. doi: 10.1016/j.jpeds.2011.06.006.
118. Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJ, Sijbrands EJ. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation. 2005;112:3168-3173. doi: 10.1161/CIRCULATIONAHA.105.565507.
119. Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol. 2008;19:362-368. doi: 10.1097/MOL.0b013e32830636e5.
120. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:3-46.
121. FH Guideline Implementation Team Toolkit. West Berkshire, UK: Heart UK. 2010.
122. Daniels SR, Gidding SS, de Ferranti SD; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(suppl):S30-S37. doi: 10.1016/j.jacl.2011.03.453.
123. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics. 2011;128(suppl 5):S213-S256.
124. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014;129(suppl 2):S46-S48]. Circulation. 2014;129(suppl 2):S1-S45. doi: 10.1161/01. cir.0000437738.63853.7a.
125. Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, De Beaufort C, De Waele K, Scheen A, Rietzschel E, Mangano A, Panier JP, Ducobu J, Langlois M, Balligand JL, Legat P, Blaton V, Muls E, Van Gaal L, Sokal E, Rooman R, Carpentier Y, De Backer G, Heller FR. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011;218:272-280. doi: 10.1016/j.atherosclerosis.2011.06.016.
126. Morris JK, Wald DS, Wald NJ. The evaluation of cascade testing for familial hypercholesterolemia. Am J Med Genet A. 2012;158A:78-84. doi: 10.1002/ajmg.a.34368.
127. Ademi Z, Watts GF, Juniper A, Liew D. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol. 2013;167:2391-2396. doi: 10.1016/j. ijcard.2013.01.280.
128. Ritchie SK, Murphy EC, Ice C, Cottrell LA, Minor V, Elliott E, Neal W. Universal versus targeted blood cholesterol screening among youth: the CARDIAC project. Pediatrics. 2010;126:260-265. doi: 10.1542/peds.2009-2546.
129. Bates TR, Burnett JR, van Bockxmeer FM, Hamilton S, Arnolda L, Watts GF. Detection of familial hypercholesterolaemia: a major treatment gap in preventative cardiology. Heart Lung Circ. 2008;17:411-413. doi: 10.1016/j.hlc.2007.06.005.
130. Bell DA, Hooper AJ, Bender R, McMahon J, Edwards G, van Bockxmeer FM, Watts GF, Burnett JR. Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Ann Clin Biochem. 2012;49(pt 6):534-537. doi: 10.1258/acb.2012.012002.
131. Huijgen R, Hutten BA, Kindt I, Vissers MN, Kastelein JJ. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet. 2012;5:354-359. doi: 10.1161/CIRCGENETICS.111.962456.
132. Gray J, Jaiyeola A, Whiting M, Modell M, Wierzbicki AS. Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart. 2008;94:754-758. doi: 10.1136/hrt.2006.107391.
133. Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, O'Brien R, Bishop W, George P, Barter PJ, Bates T, Burnett JR, Coakley J, Davidson P, Emery J, Martin A, Farid W, Freeman L, Geelhoed E, Juniper A, Kidd A, Kostner K, Krass I, Livingston M, Maxwell S, O'Leary P, Owaimrin A, Redgrave TG, Reid N, Southwell L, Suthers G, Tonkin A, Towler S, Trent R; Familial Hypercholesterolaemia Australasia Network Consensus Group (Australian Atherosclerosis Society). Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl. 2011;12:221-263. doi: 10.1016/j.atherosclerosissup.2011.06.001.
134. Suthers GK, Armstrong J, McCormack J, Trott D. Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder. J Med Genet. 2006;43:665-670. doi: 10.1136/jmg.2005.039172.
135. Hadfield SG, Horara S, Starr BJ, Yazdgerdi S, Marks D, Bhatnagar D, Cramb R, Egan S, Everdell R, Ferns G, Jones A, Marenah CB, Marples J, Prinsloo P, Sneyd A, Stewart MF, Sandle L, Wang T, Watson MS, Humphries SE; Steering Group for the Department of Health Familial Hypercholesterolaemia Cascade Testing Audit Project. Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann Clin Biochem. 2009;46(Pt 1):24-32. doi: 10.1258/acb.2008.008094.
136. Suthers GK, McCusker EA, Wake SA. Alerting genetic relatives to a risk of serious inherited disease without a patient's consent. Med J Aust. 2011;194:385-386.
137. Datta BN, McDowell IF, Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol. 2010;21:366-371. doi: 10.1097/MOL. 0b013e32833c14e2.
138. Sturm AC. The role of genetic counselors for patients with familial hypercholesterolemia. Curr Genet Med Rep. 2014;2:68-74.
139. Hilgart J, Mercer J, Thirlaway K. Individuals' experiences of, and responses to, a negative genetic test result for familial hypercholesterolaemia. J Health Psychol. 2013;18:339-349. doi: 10.1177/1359105312443403.
140. Aatre RD, Day SM. Psychological issues in genetic testing for inherited cardiovascular diseases. Circ Cardiovasc Genet. 2011;4:81-90. doi: 10.1161/CIRCGENETICS.110.957365.
141. Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, Retterstol K. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis. 2006;189:451-457. doi: 10.1016/j.atherosclerosis.2006.01.002.
142. Toleikyte I, Retterstol K, Leren TP, Iversen PO. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 2011;124:1606-1614. doi: 10.1161/CIRCULATIONAHA.110.990929.
143. Narverud I, Iversen PO, Aukrust P, Halvorsen B, Ueland T, Johansen SG, Nenseter MS, Sandset PM, Ulven SM, Ose L, Retterstol K, Holven KB. Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH. Thromb Res. 2013;131:178-182. doi: 10.1016/j.thromres.2012.11.008.
144. Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680-2690. doi: 10.1172/JCI119813.
145. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2014;7:CD006401. doi: 10.1002/14651858.CD006401.pub3.
146. Deleted in proof.
147. Kusters DM, Avis HJ, de Groot E, Wijburg FA, Kastelein JJ, Wiegman A, Hutten BA. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA. 2014;312:1055-1057. doi: 10.1001/jama.2014.8892.
148. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA; National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(suppl):S58-S71. doi: 10.1016/j.jacl.2014.03.004.
149. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-1509. doi: 10.1056/NEJMoa1500858.
150. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499. doi: 10.1056/NEJMoa1501031.
151. Maron DJ, Boden WE, Weintraub WS, Calfas KJ, O'Rourke RA. Is optimal medical therapy as used in the COURAGE trial feasible for widespread use? Curr Treat Options Cardiovasc Med. 2011;13:16-25. doi: 10.1007/s11936-010-0104-7.
152. Gidding SS, Daniels SR, Kavey RE; Expert Panel on Cardiovascular Health and Risk Reduction in Youth. Developing the 2011 integrated pediatric guidelines for cardiovascular risk reduction. Pediatrics. 2012;129:e1311-e1319. doi: 10.1542/peds.2011-2903.
153. O'Brien EC, Roe MT, Fraulo ES, Peterson ED, Ballantyne CM, Genest J, Gidding SS, Hammond E, Hemphill LC, Hudgins LC, Kindt I, Moriarty PM, Ross J, Underberg JA, Watson K, Pickhardt D, Rader DJ, Wilemon K, Knowles JW. Rationale and design of the familial hypercholesterolemia foundation cascade screening for awareness and detection of familial hypercholesterolemia registry. Am Heart J. 2014;167:342-349.e17.
154. Raal FJ, Pilcher GJ, Illingworth DR, Pappu AS, Stein EA, Laskarzewski P, Mitchel YB, Melino MR. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997;135:249-256.
155. Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black DM. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000;150:421-428.
156. Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Palmer M, Wilpshaar W. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008;197:400-406. doi: 10.1016/j. atherosclerosis.2007.06.028.
157. Marais AD, Blom DJ, Firth JC. Statins in homozygous familial hypercholesterolemia. Curr Atheroscler Rep. 2002;4:19-25.
158. Ooi EM, Barrett PH, Watts GF. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies. Int J Cardiol. 2013;168:1811-1818. doi: 10.1016/j.ijcard.2013.06.069.
159. Gagne C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469-2475.
160. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006. doi: 10.1016/S0140-6736(10)60284-X.
161. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ; Phase 3 HoFH Lomitapide Study Investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a singlearm, open-label, phase 3 study. Lancet. 2013;381:40-46. doi: 10.1016/S0140-6736(12)61731-0.
162. Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. JAMA Intern Med. 2014;174:443-447. doi: 10.1001/jamainternmed.2013.13309.
163. Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, Mittleman RS. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an openlabel extension. Eur Heart J. 2015;36:566-575. doi: 10.1093/eurheartj/eht549.
164. European Medical Agencies. http://www.ema.europa.edu. Accessed September 3, 2015.
165. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two firstin-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129:1022-1032. doi: 10.1161/CIRCULATIONAHA.113.001292.
166. Risk Evaluation and Mitigation Strategy (REMS): JUXTAPID (lomitapide) capsules. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM333438.pdf. Accessed September 3, 2015.
167. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408-2417. doi: 10.1161/CIRCULATIONAHA.112.144055.
168. Wierzbicki AS, Viljoen A, Hardman TC, Mikhailidis DP. New therapies to reduce low-density lipoprotein cholesterol. Curr Opin Cardiol. 2013;28:452-457. doi: 10.1097/HCO.0b013e3283605fa2.
169. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128:2113-2120. doi: 10.1161/CIRCULATIONAHA.113.004678.
170. Marais AD, Blom DJ. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Curr Opin Lipidol. 2013;24:288-294. doi: 10.1097/MOL.0b013e32836308bc.
171. Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl. 2013;14:19-27. doi: 10.1016/j. atherosclerosissup.2012.10.021.
172. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83-177. doi: 10.1002/jca.20240.
173. Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler Suppl. 2013;14:67-70. doi: 10.1016/j.atherosclerosissup.2012.10.001.
174. Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Longterm safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102:1199-1204. doi: 10.1016/j.amjcard.2008.06.049.
175. Thompson GR; HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198:247-255. doi: 10.1016/j.atherosclerosis.2008.02.009.
176. Al-Shaikh AM, Abdullah MH, Barclay A, Cullen-Dean G, McCrindle BW. Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia. Cardiol Young. 2002;12:105-112.
177. Maiorana A, Nobili V, Calandra S, Francalanci P, Bernabei S, El Hachem M, Monti L, Gennari F, Torre G, de Ville de Goyet J, Bartuli A. Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr Transplant. 2011;15:E25-E29. doi: 10.1111/j.1399-3046.2010.01383.x.
178. Moyle M, Tate B. Homozygous familial hypercholesterolaemia presenting with cutaneous xanthomas: response to liver transplantation. Australas J Dermatol. 2004;45:226-228. doi: 10.1111/j.1440-0960.2004.00103.x.
179. Palacio CH, Harring TR, Nguyen NT, Goss JA, O'Mahony CA. Homozygous familial hypercholesterolemia: case series and review of the literature. Case Rep Transplant. 2011;2011:154908. doi: 10.1155/2011/154908.
180. Ibrahim M, El-Hamamsy I, Barbir M, Yacoub MH. Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively. J Cardiovasc Transl Res. 2012;5:351-358. doi: 10.1007/s12265-011-9311-1.
181. Schmidt HH, Tietge UJ, Buettner J, Barg-Hock H, Offner G, Schweitzer S, Dedoussis GV, Rodeck B, Kallfelz HC, Schlitt HJ, Oldhafer K, Klempnauer J. Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous p.W577R LDL-receptor gene mutation. Clin Transplant. 2008;22:180-184. doi: 10.1111/j.1399-0012.2007.00764.x.
182. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ. 2002;324:1303.
183. Nherera L, Marks D, Minhas R, Thorogood M, Humphries SE. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart. 2011;97:1175-1181. doi: 10.1136/hrt.2010.213975.
184. Wonderling D, Umans-Eckenhausen MA, Marks D, Defesche JC, Kastelein JJ, Thorogood M. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in the Netherlands. Semin Vasc Med. 2004;4:97-104. doi: 10.1055/s-2004-822992.
185. Oliva J, Lopez-Bastida J, Moreno SG, Mata P, Alonso R. Costeffectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia [in Spanish]. Rev Esp Cardiol. 2009;62:57-65.
186. Langslet G, Ose L. Screening methods in the diagnosis and assessment of children and adolescents with familial hypercholesterolemia. Expert Rev Cardiovasc Ther. 2013;11:1061-1066. doi: 10.1586/14779072.2013.814851.
187. Minhas R, Humphries SE, Qureshi N, Neil HA; NICE Guideline Development Group. Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart. 2009;95:584-587. doi: 10.1136/hrt.2008.162909.
188. Watts GF, Juniper A, van Bockxmeer F, Ademi Z, Liew D, O'Leary P. Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations [published correction appears in Int J Evid Based Healthc. 2012;10:419]. Int J Evid Based Healthc. 2012;10:211-221. doi: 10.1111/j.1744-1609.2012.00272.x.
189. Davidson P, Halcomb E, Hickman L, Phillips J, Graham B. Beyond the rhetoric: what do we mean by a "model of care"? Aust J Adv Nurs. 2006;23:47-55.
190. Huijgen R, Kindt I, Verhoeven SB, Sijbrands EJ, Vissers MN, Kastelein JJ, Hutten BA. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One. 2010;5:e9220. doi: 10.1371/journal. pone.0009220.
191. Mata N, Alonso R, Badimon L, Padro T, Fuentes F, Muniz O, Perez-Jimenez F, Lopez-Miranda J, Diaz JL, Vidal JI, Barba A, Piedecausa M, Sanchez JF, Irigoyen L, Guallar E, Ordovas JM, Mata P. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis. 2011;10:94. doi: 10.1186/1476-511X-10-94.
192. Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra K, Black HR, Blumenthal RS, Davidson MH, Fazio SB, Ferdinand KC, Fine LJ, Fonseca V, Franklin BA, McBride PE, Mensah GA, Merli GJ, O'Gara PT, Thompson PD, Underberg JA. ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease). Circulation. 2009;120:e100-e126. doi: 10.1161/CIRCULATIONAHA.109.192640.
193. Qureshi N, Humphries SE, Seed M, Rowlands P, Minhas R; NICE Guideline Development Group. Identification and management of familial hypercholesterolaemia: what does it mean to primary care? Br J Gen Pract. 2009;59:773-776. doi: 10.3399/bjgp09X472674.
194. Bell DA, Garton-Smith J, Vickery A, Kirke AB, Pang J, Bates TR, Watts GF. Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia. Heart Lung Circ. 2014;23:309-313. doi: 10.1016/j.hlc.2013.08.005.
195. Stephenson SH, Larrinaga-Shum S, Hopkins PN. Benefits of the MEDPED treatment support program for patients with familial hypercholesterolemia. J Clin Lipidol. 2009;3:94-100. doi: 10.1016/j.jacl.2009.02.004.
196. Martin AC, Coakley J, Forbes DA, Sullivan DR, Watts GF. Familial hypercholesterolaemia in children and adolescents: a new paediatric model of care. J Paediatr Child Health. 2013;49:E263-E272. doi: 10.1111/jpc.12036.
197. Allen JK, Dennison Himmelfarb CR, Szanton SL, Frick KD. Costeffectiveness of nurse practitioner/community health worker care to reduce cardiovascular health disparities. J Cardiovasc Nurs. 2014;29:308-314. doi: 10.1097/JCN.0b013e3182945243.
198. Krass I, Walker AT, Watts GF. Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist? Int J Clin Pharm. 2012;34:501-505. doi: 10.1007/s11096-012-9646-y.
199. Watts GF, Sullivan DR, van Bockxmeer FM, Poplawski N, Hamilton-Craig I, Clifton PM, O'Brien RC, Bishop W, George PM, Semsarian C, Tonkin A; Familial Hypercholesterolaemia Australasia Network. A new model of care for familial hypercholesterolaemia: what is the role of cardiology? Heart Lung Circ. 2012;21:543-550. doi: 10.1016/j. hlc.2012.04.010.
200. Hammond E, Watts GF, Rubinstein Y, Farid W, Livingston M, Knowles JW, Lochmuller H, Bellgard M, Dawkins HJ. Role of international registries in enhancing the care of familial hypercholesterolaemia. Int J Evid Based Healthc. 2013;11:134-139. doi: 10.1111/1744-1609.12023.
201. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357:165-168. doi: 10.1016/S0140-6736(00)03587-X.
202. Al-Sarraf A, Allard M, Martinka M, Frohlich J. Regional and national familial hypercholesterolemia registries: present international application, importance, and needs for Canada. Can J Cardiol. 2013;29:6-9. doi: 10.1016/j.cjca.2012.04.019.
203. Building Blocks for Action Innovative Care for Chronic Conditions: Global Report. Geneva, Switzerland: World Health Organization; 2002.
204. Aarden E, Van Hoyweghen I, Horstman K. The paradox of public health genomics: definition and diagnosis of familial hypercholesterolaemia in three European countries. Scand J Public Health. 2011;39:634-639. doi: 10.1177/1403494811414241.
205. Royal College of Physicians. National Audit of the Management of Familial Hypercholesterolemia. http://www.rcplondon.ac.uk/node/2584. Accessed September 3, 2015.
206. Goldberg AC, Robinson JG, Cromwell WC, Ross JL, Ziajka PE. Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(suppl):S46-S51. doi: 10.1016/j.jacl.2011.04.002.